Vivotif--a 'magic shield' for protection against typhoid fever and delivery of heterologous antigens

Chemotherapy. 2007;53(3):177-80. doi: 10.1159/000100515. Epub 2007 Mar 7.

Abstract

The attenuated Salmonella typhi strain Ty21a is the main constituent of Vivotif, the only attenuated live oral vaccine against typhoid fever. In comparison with antibiotics, the 'magic bullets' which Paul Ehrlich was striving for to treat infectious diseases, this vaccine should be viewed as a 'magic shield', because rather than treating typhoid fever after the infection has started, immunisation with this vaccine strain prevents infection and disease by the induction of specific immune responses. Ty21a is also an attractive carrier for the delivery of heterologous antigens. Recently, we successfully used Ty21a for antigen delivery via the haemolysin secretion system of Escherichia coli, which allows efficient protein secretion from the carrier bacteria.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antigens, Heterophile / immunology*
  • Escherichia coli Proteins / genetics
  • Escherichia coli Proteins / immunology
  • Genetic Vectors
  • Hemolysin Proteins / genetics
  • Hemolysin Proteins / immunology
  • Humans
  • Polysaccharides, Bacterial*
  • Salmonella typhi / genetics
  • Salmonella typhi / immunology
  • Typhoid Fever / prevention & control*
  • Typhoid-Paratyphoid Vaccines*
  • Vaccines, Attenuated*

Substances

  • Antigens, Heterophile
  • Escherichia coli Proteins
  • Hemolysin Proteins
  • Polysaccharides, Bacterial
  • Ty21a typhoid vaccine
  • Typhoid-Paratyphoid Vaccines
  • Vaccines, Attenuated